In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis Clinical Trial

Official title:

In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02582385
• Other study ID #: CHUB-ALS
• Status: Completed
• Phase: N/A
• First received: October 20, 2015
• Last updated: October 20, 2015
• Start date: October 2012
• Est. completion date: February 2015

Study information

• Verified date: October 2015
• Source: Brugmann University Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicines and Health Products, FAMHP
• Study type: Observational

Clinical Trial Summary

The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• patients who died with amyotrophic lateral sclerosis, having been autopsied.

Exclusion Criteria:

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• in-situ cytokine expression

Locations

Country	Name	City	State
Belgium	CHU Brugmann	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Brugmann University Hospital

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	in situ cytokine detection: interleukin 18	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005	No
Primary	in situ cytokine detection: interleukin 1	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005	No
Primary	in situ cytokine detection: interleukin 6	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005	No
Primary	in situ cytokine detection:TNF-a	IHC detection on histopathology sections of paraffin embedded brain tissue.	retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005	No